Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f

International Journal of Cancer

Volumn 136, Issue 7, 2015, Pages 1579-1588

  Harvey, Harry ^a,b   Piskareva, Olga ^a,b   Creevey, Laura ^a,b   Alcock, Leah C ^a,b   Buckley, Patrick G ^a,b   O'Sullivan, Maureen J ^b   Segura, Miguel F ^c   Gallego, Soledad ^c   Stallings, Raymond L ^a,b   Bray, Isabella M ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cisplatin; Drug resistance; miR 520f; NAIP; Neuroblastoma

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 520F; NEURONAL APOPTOSIS INHIBITORY PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CISPLATIN; MIRN520 MICRORNA, HUMAN;

ARTICLE; CANCER RESISTANCE; CHROMOSOME 5; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; NEURAL APOPTOSIS INHIBITORY PROTEIN GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MICRORNAS; NEUROBLASTOMA; NEURONAL APOPTOSIS-INHIBITORY PROTEIN; PHENOTYPE; RNA INTERFERENCE;

EID: 84920989634     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29144     Document Type: Article

References (42)

1. London WB, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol 2011;29:3286-92.
2. Vandesompele J, Baudis M, De Preter K, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005;23:2280-99.
3. Siddik Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
4. Haber M, Smith J, Bordow SB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006;24:1546-53.
5. Huynh T, Norris MD, Haber M, Henderson MJ. ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma. Front Oncol 2012;2:178.
6. Manohar CF, Bray JA, Salwen HR, et al. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 2004;23:753-62.
7. Porro A, Haber M, Diolaiti D, et al. Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J Biol Chem 2010;285:19532-43.
8. Ryan J, Tivnan A, Fay J, et al. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer 2012;107:967-76.
9. Creevey L, Ryan J, Harvey H, et al. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer 2013;12:23.
10. Foley NH, Bray IM, Tivnan A, et al. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 2010;9:83.
11. Foley NH, Bray I, Watters KM, et al. MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ 2011;18:1089-98.
12. Bray I, Tivnan A, Bryan K, et al. MicroRNA-542-5p as a novel tumour suppressor in neuroblastoma. Cancer Lett 2011;303:56-64.
13. Lynch J, Fay J, Meehan M, et al. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis 2012;33:976-85.
14. Liston P, Roy N, Tamai K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996;379:349-53.
15. Davoodi J, Ghahremani MH, Es-Haghi A, et al. Neuronal apoptosis inhibitory protein, NAIP, is an inhibitor of procaspase-9. Int J Biochem Cell Biol 2010;42:958-64.
16. De Preter K, Mestdagh P, Vermeulen J, et al. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumour samples. Clin Cancer Res 2011;17:7684-92.
17. Martin A, Clynes M. Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology 1993;11:49-58.
18. Selzer RR, Richmond TA, Pofahl NJ, et al. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 2005;44:305-19.
19. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 2009;10:R64.
20. Ozols R. F. Chemotherapy for advanced epithelial ovarian cancer. Hematol Oncol Clin North Am 1992;6:879-94.
21. Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-8.
22. Dijkstra JR, Mekenkamp LJ, Teerenstra S, et al. MicroRNA expression in formalin-fixed paraffin embedded tissue using real time quantitative PCR: the strengths and pitfalls. J Cell Mol Med 2012;16:683-90.
23. Romanish MT, Nakamura H, Lai CB, et al. A novel protein isoform of the multicopy human NAIP gene derives from intragenic Alu SINE promoters. PloS One 2009;4:e5761.
24. Schmutz J, Martin J, Terry A, et al. The DNA sequence and comparative analysis of human chromosome 5. Nature 2004;431:268-74.
25. Choi J, Hwang YK, Choi YJ, et al. Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer. J Korean Med Sci 2007;22 Suppl: S17-23.
26. Nakagawa Y, Hasegawa M, Kurata M, et al. Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL). Am J Hematol 2005;78:173-80.
27. Lukiw WJ, Cui JG, Li YY, Culicchia F. Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). J Neuro-Oncol 2009;91:27-32.
28. Saleem M, Qadir MI, Perveen N, et al. Inhibitors of apoptotic proteins: new targets for anticancer therapy. Chem Biol Drug Des 2013;82:243-51.
29. Maier JK, Lahoua Z, Gendron NH, et al. The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J Neurosci 2002;22:2035-43.
30. Karimpour S, Davoodi J, Ghahremani MH. Integrity of ATP binding site is essential for effective inhibition of the intrinsic apoptosis pathway by NAIP. Biochem Biophys Res Commun 2011;407:158-62.
31. Valentijn LJ, Koster J, Haneveld F, et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci USA 2012;109:19190-5.
32. Keklikoglou I, Koerner C, Schmidt C, et al. MicroRNA-520/373 family functions as a tumour suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene 2012;31:4150-63.
33. Liu J, Zhang D, Luo W, et al. E3 ligase activity of XIAP RING domain is required for XIAP-mediated cancer cell migration, but not for its RhoGDI binding activity. PloS One 2012;7:e35682.
34. Cheung HH, Plenchette S, Kern CJ, et al. The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways. Mol Biol Cell 2008;19:2729-40.
35. Oberoi-Khanuja TK, Murali A, Rajalingam K. IAPs on the move: role of inhibitors of apoptosis proteins in cell migration. Cell Death Dis 2013;4:e784.
36. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010;70:7027-30.
37. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther 2011;18:1121-6.
38. LaCasse E. C. Pulling the plug on a cancer cell by eliminating XIAP with AEG35156. Cancer Lett 2013;332:215-24.
39. Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007;131:669-81.
40. Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007;131:682-93.
41. Fulda S. Molecular pathways: targeting inhibitor of apoptosis proteins in cancer-from molecular mechanism to therapeutic application. Clin Cancer Res 2014;20:289-95.
42. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012;11:109 24.